vs
Alkermes plc.（ALKS）与UiPath, Inc.（PATH）财务数据对比。点击上方公司名可切换其他公司
UiPath, Inc.的季度营收约是Alkermes plc.的1.1倍（$411.1M vs $384.5M），UiPath, Inc.净利率更高（48.4% vs 12.8%，领先35.5%），UiPath, Inc.同比增速更快（15.9% vs -10.6%），Alkermes plc.自由现金流更多（$170.0M vs $25.1M），过去两年Alkermes plc.的营收复合增速更高（4.8% vs 0.7%）
Alkermes plc是一家全产业链布局的生物制药企业，专注于精神障碍与神经系统疾病相关药物的研发。公司1987年由迈克尔·沃尔创立，2011年9月与原Élan集团旗下的药物制剂及生产部门Elan Drug Technologies合并，总部位于都柏林，在马萨诸塞州沃尔瑟姆设有研发中心，俄亥俄州威尔明顿建有生产基地。
UiPath是一家全球化软件企业，专注于开发人工智能、智能自动化及流程编排类软件，其产品支持用户搭建与调度AI代理，实现复杂业务流程、工作流的自动化运行，助力各行业客户提升运营效率、降低人力成本。
ALKS vs PATH — 直观对比
营收规模更大
PATH
是对方的1.1倍
$384.5M
营收增速更快
PATH
高出26.5%
-10.6%
净利率更高
PATH
高出35.5%
12.8%
自由现金流更多
ALKS
多$144.9M
$25.1M
两年增速更快
ALKS
近两年复合增速
0.7%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $384.5M | $411.1M |
| 净利润 | $49.3M | $198.8M |
| 毛利率 | 88.0% | 83.3% |
| 营业利润率 | 15.1% | 3.2% |
| 净利率 | 12.8% | 48.4% |
| 营收同比 | -10.6% | 15.9% |
| 净利润同比 | -66.3% | 1966.2% |
| 每股收益（稀释后） | $0.29 | $0.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALKSPATH
| Q4 25 | $384.5M | $411.1M | ||
| Q3 25 | $394.2M | $361.7M | ||
| Q2 25 | $390.7M | $356.6M | ||
| Q1 25 | $306.5M | $423.6M | ||
| Q4 24 | $430.0M | $354.7M | ||
| Q3 24 | $378.1M | $316.3M | ||
| Q2 24 | $399.1M | $335.1M | ||
| Q1 24 | $350.4M | $405.3M |
净利润ALKSPATH
| Q4 25 | $49.3M | $198.8M | ||
| Q3 25 | $82.8M | $1.6M | ||
| Q2 25 | $87.1M | $-22.6M | ||
| Q1 25 | $22.5M | $51.8M | ||
| Q4 24 | $146.5M | $-10.7M | ||
| Q3 24 | $92.4M | $-86.1M | ||
| Q2 24 | $91.4M | $-28.7M | ||
| Q1 24 | $36.8M | $33.9M |
毛利率ALKSPATH
| Q4 25 | 88.0% | 83.3% | ||
| Q3 25 | 86.9% | 82.2% | ||
| Q2 25 | 87.3% | 82.1% | ||
| Q1 25 | 83.9% | 84.8% | ||
| Q4 24 | 85.6% | 82.0% | ||
| Q3 24 | 83.3% | 80.0% | ||
| Q2 24 | 84.6% | 83.5% | ||
| Q1 24 | 83.3% | 86.8% |
营业利润率ALKSPATH
| Q4 25 | 15.1% | 3.2% | ||
| Q3 25 | 22.6% | -5.6% | ||
| Q2 25 | 23.8% | -4.6% | ||
| Q1 25 | 4.5% | 7.9% | ||
| Q4 24 | 37.8% | -12.2% | ||
| Q3 24 | 27.7% | -32.7% | ||
| Q2 24 | 27.5% | -14.8% | ||
| Q1 24 | 12.4% | 3.7% |
净利率ALKSPATH
| Q4 25 | 12.8% | 48.4% | ||
| Q3 25 | 21.0% | 0.4% | ||
| Q2 25 | 22.3% | -6.3% | ||
| Q1 25 | 7.3% | 12.2% | ||
| Q4 24 | 34.1% | -3.0% | ||
| Q3 24 | 24.4% | -27.2% | ||
| Q2 24 | 22.9% | -8.6% | ||
| Q1 24 | 10.5% | 8.4% |
每股收益（稀释后）ALKSPATH
| Q4 25 | $0.29 | $0.37 | ||
| Q3 25 | $0.49 | $0.00 | ||
| Q2 25 | $0.52 | $-0.04 | ||
| Q1 25 | $0.13 | $0.09 | ||
| Q4 24 | $0.88 | $-0.02 | ||
| Q3 24 | $0.55 | $-0.15 | ||
| Q2 24 | $0.53 | $-0.05 | ||
| Q1 24 | $0.21 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $388.6M | $1.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.8B | $1.9B |
| 总资产 | $2.5B | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALKSPATH
| Q4 25 | $388.6M | $1.4B | ||
| Q3 25 | $616.4M | $1.4B | ||
| Q2 25 | $521.2M | $1.6B | ||
| Q1 25 | $399.8M | $1.6B | ||
| Q4 24 | $291.1M | $1.6B | ||
| Q3 24 | $396.3M | $1.7B | ||
| Q2 24 | $535.1M | $1.9B | ||
| Q1 24 | $420.8M | $1.9B |
股东权益ALKSPATH
| Q4 25 | $1.8B | $1.9B | ||
| Q3 25 | $1.7B | $1.7B | ||
| Q2 25 | $1.6B | $1.7B | ||
| Q1 25 | $1.5B | $1.8B | ||
| Q4 24 | $1.5B | $1.7B | ||
| Q3 24 | $1.3B | $1.8B | ||
| Q2 24 | $1.3B | $2.0B | ||
| Q1 24 | $1.3B | $2.0B |
总资产ALKSPATH
| Q4 25 | $2.5B | $2.9B | ||
| Q3 25 | $2.3B | $2.6B | ||
| Q2 25 | $2.3B | $2.6B | ||
| Q1 25 | $2.1B | $2.9B | ||
| Q4 24 | $2.1B | $2.7B | ||
| Q3 24 | $2.2B | $2.7B | ||
| Q2 24 | $2.2B | $2.8B | ||
| Q1 24 | $2.1B | $3.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $170.1M | $28.3M |
| 自由现金流经营现金流 - 资本支出 | $170.0M | $25.1M |
| 自由现金流率自由现金流/营收 | 44.2% | 6.1% |
| 资本支出强度资本支出/营收 | 0.0% | 0.8% |
| 现金转化率经营现金流/净利润 | 3.45× | 0.14× |
| 过去12个月自由现金流最近4个季度 | $480.3M | — |
8季度趋势，按日历期对齐
经营现金流ALKSPATH
| Q4 25 | $170.1M | $28.3M | ||
| Q3 25 | $101.7M | $41.6M | ||
| Q2 25 | $150.2M | $119.0M | ||
| Q1 25 | $98.8M | $146.1M | ||
| Q4 24 | $190.4M | $28.1M | ||
| Q3 24 | $81.6M | $46.4M | ||
| Q2 24 | $146.0M | $100.0M | ||
| Q1 24 | $21.1M | $145.6M |
自由现金流ALKSPATH
| Q4 25 | $170.0M | $25.1M | ||
| Q3 25 | $84.4M | — | ||
| Q2 25 | $137.2M | $106.2M | ||
| Q1 25 | $88.7M | $138.7M | ||
| Q4 24 | $180.6M | $23.2M | ||
| Q3 24 | $73.3M | $45.0M | ||
| Q2 24 | $138.9M | $98.8M | ||
| Q1 24 | $12.8M | $141.8M |
自由现金流率ALKSPATH
| Q4 25 | 44.2% | 6.1% | ||
| Q3 25 | 21.4% | — | ||
| Q2 25 | 35.1% | 29.8% | ||
| Q1 25 | 28.9% | 32.7% | ||
| Q4 24 | 42.0% | 6.5% | ||
| Q3 24 | 19.4% | 14.2% | ||
| Q2 24 | 34.8% | 29.5% | ||
| Q1 24 | 3.6% | 35.0% |
资本支出强度ALKSPATH
| Q4 25 | 0.0% | 0.8% | ||
| Q3 25 | 4.4% | 0.0% | ||
| Q2 25 | 3.3% | 3.6% | ||
| Q1 25 | 3.3% | 1.7% | ||
| Q4 24 | 2.3% | 1.4% | ||
| Q3 24 | 2.2% | 0.4% | ||
| Q2 24 | 1.8% | 0.4% | ||
| Q1 24 | 2.4% | 0.9% |
现金转化率ALKSPATH
| Q4 25 | 3.45× | 0.14× | ||
| Q3 25 | 1.23× | 26.25× | ||
| Q2 25 | 1.72× | — | ||
| Q1 25 | 4.40× | 2.82× | ||
| Q4 24 | 1.30× | — | ||
| Q3 24 | 0.88× | — | ||
| Q2 24 | 1.60× | — | ||
| Q1 24 | 0.57× | 4.29× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALKS
| Vivitrol | $124.1M | 32% |
| Aristada And Aristada Initio | $97.2M | 25% |
| LYBALVI | $94.1M | 24% |
| Royalty | $65.7M | 17% |
| Manufacturing Revenue | $3.3M | 1% |
PATH
| Subscription Services | $247.6M | 60% |
| License | $150.0M | 36% |
| Professional Services And Other | $13.5M | 3% |
